Early Mortality in a Multinational Systemic Sclerosis Inception Cohort

Arthritis and Rheumatology

Volumn 69, Issue 5, 2017, Pages 1067-1077

  Hao, Yanjie ^a,b   Hudson, Marie ^c,h   Baron, M ^h   Carreira, Patricia ^d   Stevens, Wendy ^a   Rabusa, Candice ^a   Tatibouet, Solene ^e   Carmona, Loreto ^f   Joven, Beatriz E ^d   Huq, Molla ^a   Proudman, Susanna ^g   Nikpour, M ^h   Abu Hakima, M ^h   Cabral, A R ^h   Docherty, P ^h   Fortin, P R ^h   Fritzler, M ^h   Grodzicky, T ^h   Gyger, G ^h   Jones, N ^h   Kaminska, E ^h   Khalidi, N ^h   Larche M ^h   LeClercq, S ^h   Ligier, S ^h   Markland, J ^h   Masetto, A ^h   Mathieu, J P ^h   Pope, J ^h   Robinson, D ^h   Rodriguez Reyna, T S ^h   Smith, D ^h   Sutton, E ^h   Thorne, C ^h   Proudman, S ^h   Roddy, J ^h   Sahhar, J ^h   Stevens, W ^h   Walker, J ^h   Youssef, P ^h   Zochling, J ^h   more..

^a ST VINCENT S HOSPITAL   (Australia)

^b PEKING UNIVERSITY FIRST HOSPITAL   (China)

^c MCGILL UNIVERSITY   (Canada)

^d HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

^e MCGILL UNIVERSITY   (Canada)

^f Instituto de Salud Musculoesquelética InMusc Calle Hilarión Eslava   (Spain)

^g ROYAL ADELAIDE HOSPITAL   (Australia)

^h Royal Adelaide Hospital and University of Adelaide ^*  (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; ARTICLE; CAUSE OF DEATH; CEREBROVASCULAR DISEASE; CONTROLLED STUDY; DISEASE DURATION; FEMALE; FINGER ULCER; FOLLOW UP; HUMAN; ISCHEMIC HEART DISEASE; KIDNEY DISEASE; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MORTALITY; PERICARDIAL EFFUSION; PRIORITY JOURNAL; PULMONARY HYPERTENSION; STANDARDIZED MORTALITY RATIO; SYSTEMIC SCLEROSIS; AGED; AUSTRALIA; CANADA; COHORT ANALYSIS; COMPLICATION; HEART DISEASES; HEART MUSCLE ISCHEMIA; HYPERTENSION, PULMONARY; IMMUNOLOGY; INTESTINAL DISEASES; KAPLAN MEIER METHOD; KIDNEY DISEASES; LUNG DISEASES, INTERSTITIAL; NEOPLASM; PROGNOSIS; SEPSIS; SPAIN;

AUTOANTIBODY;

ADULT; AGED; AUSTRALIA; AUTOANTIBODIES; CANADA; CAUSE OF DEATH; CEREBROVASCULAR DISORDERS; COHORT STUDIES; FEMALE; HEART DISEASES; HUMANS; HYPERTENSION, PULMONARY; INTESTINAL DISEASES; KAPLAN-MEIER ESTIMATE; KIDNEY DISEASES; LUNG DISEASES, INTERSTITIAL; MALE; MIDDLE AGED; MORTALITY; MYOCARDIAL ISCHEMIA; NEOPLASMS; PROGNOSIS; SCLERODERMA, SYSTEMIC; SEPSIS; SPAIN;

EID: 85017417416     PISSN: 23265191     EISSN: 23265205     Source Type: Journal    
DOI: 10.1002/art.40027     Document Type: Article

References (31)

1. Denton CP. Systemic sclerosis: from pathogenesis to targeted therapy. Clin Exp Rheumatol 2015;33 Suppl 92:S3–7.
2. Stern EP, Denton CP. The pathogenesis of systemic sclerosis. Rheum Dis Clin North Am 2015;41:367–82.
3. Gu YS, Kong J, Cheema GS, Keen CL, Wick G, Gershwin ME. The immunobiology of systemic sclerosis. Semin Arthritis Rheum 2008;38:132–60.
4. Asano Y, Sato S. Vasculopathy in scleroderma. Semin Immunopathol 2015;37:489–500.
5. Bennett R, Bluestone R, Holt PJ, Bywaters EG. Survival in scleroderma. Ann Rheum Dis 1971;30:581–8.
6. Tyndall AJ, Bannert B, Vonk M, Airò P, Cozzi F, Carreira PE, et al. Causes and risk factors for death in systemic sclerosis: a study from the EULAR Scleroderma Trials and Research (EUSTAR) database. Ann Rheum Dis 2010;69:1809–15.
7. Subcommittee for Scleroderma Criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee. Preliminary criteria for the classification of systemic sclerosis (scleroderma). Arthritis Rheum 1980;23:581–90.
8. Andersen PK, Borgan O, Gill RD, Keiding N. Statistical models based on counting processes. New York: Springer-Verlag; 1993. p. 322.
9. Mok CC, Kwok CL, Ho LY, Chan PT, Yip SF. Life expectancy, standardized mortality ratios, and causes of death in six rheumatic diseases in Hong Kong, China. Arthritis Rheum 2011;63:1182–9.
10. Chiang CL. The life table and its construction. In: Introduction to stochastic processes in biostatistics. New York: John Wiley & Sons; 1968. p. 189–214.
11. Newell C. Methods and models in demography. Chichester (UK): John Wiley & Sons; 1994. p. 63–81.
12. Sampaio-Barros PD, Bortoluzzo AB, Marangoni RG, Rocha LF, del Rio AP, Samara AM, et al. Survival, causes of death, and prognostic factors in systemic sclerosis: analysis of 947 Brazilian patients. J Rheumatol 2012;39:1971–8.
13. Nihtyanova SI, Schreiber BE, Ong VH, Rosenberg D, Moinzadeh P, Coghlan JG, et al. Prediction of pulmonary complications and long-term survival in systemic sclerosis. Arthritis Rheumatol 2014;66:1625–35.
14. Joven BE, Almodovar R, Carmona L, Carreira PE. Survival, causes of death, and risk factors associated with mortality in Spanish systemic sclerosis patients: results from a single university hospital. Semin Arthritis Rheum 2010;39:285–93.
15. Hoffmann-Vold AM, Molberg Ø, Midtvedt Ø, Garen T, Gran JT. Survival and causes of death in an unselected and complete cohort of Norwegian patients with systemic sclerosis. J Rheumatol 2013;40:1127–33.
16. Vettori S, Cuomo G, Abignano G, Iudici M, Valentini G. Survival and death causes in 251 systemic sclerosis patients from a single Italian center. Reumatismo 2010;62:202–9. In Italian.
17. Elhai M, Meune C, Avouac J, Kahan A, Allanore Y. Trends in mortality in patients with systemic sclerosis over 40 years: a systematic review and meta-analysis of cohort studies. Rheumatology (Oxford) 2012;51:1017–26.
18. Jacobsen S, Halberg P, Ullman S. Mortality and causes of death of 344 Danish patients with systemic sclerosis (scleroderma). Br J Rheumatol 1998;37:750–5.
19. Bulpitt KJ, Clements PJ, Lachenbruch PA, Paulus HE, Peter JB, Agopian MS, et al. Early undifferentiated connective tissue disease. Part III. Outcome and prognostic indicators in early scleroderma (systemic sclerosis). Ann Intern Med 1993;118:602–9.
20. Jacobsen S, Ullman S, Shen GQ, Wiik A, Halberg P. Influence of clinical features, serum antinuclear antibodies, and lung function on survival of patients with systemic sclerosis. J Rheumatol 2001;28:2454–9.
21. Bryan C, Knight C, Black CM, Silman AJ. Prediction of five-year survival following presentation with scleroderma: development of a simple model using three disease factors at first visit. Arthritis Rheum 1999;42:2660–5.
22. Bryan C, Howard Y, Brennan P, Black C, Silman A. Survival following the onset of scleroderma: results from a retrospective inception cohort study of the UK patient population. Br J Rheumatol 1996;35:1122–6.
23. Domsic RT, Nihtyanova SI, Wisniewski SR, Fine MJ, Lucas M, Kwoh CK, et al. Derivation and external validation of a prediction rule for five-year mortality in patients with early diffuse cutaneous systemic sclerosis. Arthritis Rheumatol 2016;68:993–1003.
24. Strickland G, Pauling J, Cavill C, Shaddick G, McHugh N. Mortality in systemic sclerosis: a single centre study from the UK. Clin Rheumatol 2013;32:1533–9.
25. Fransen J, Popa-Diaconu D, Hesselstrand R, Carreira P, Valentini G, Beretta L, et al. Clinical prediction of 5-year survival in systemic sclerosis: validation of a simple prognostic model in EUSTAR centres. Ann Rheum Dis 2011;70:1788–92.
26. Steen VD, Medsger TA. Changes in causes of death in systemic sclerosis, 1972–2002. Ann Rheum Dis 2007;66:940–4.
27. Williams MH, Das C, Handler CE, Akram MR, Davar J, Denton CP, et al. Systemic sclerosis associated pulmonary hypertension: improved survival in the current era. Heart 2006;92:926–32.
28. Lefevre G, Dauchet L, Hachulla E, Montani D, Sobanski V, Lambert M, et al. Survival and prognostic factors in systemic sclerosis–associated pulmonary hypertension: a systematic review and meta-analysis. Arthritis Rheum 2013;65:2412–23.
29. Ngian GS, Sahhar J, Proudman SM, Stevens W, Wicks IP, van Doornum S. Prevalence of coronary heart disease and cardiovascular risk factors in a national cross-sectional cohort study of systemic sclerosis. Ann Rheum Dis 2012;71:1980–3.
30. Dave AJ, Fiorentino D, Lingala B, Krishnan E, Chung L. Atherosclerotic cardiovascular disease in hospitalized patients with systemic sclerosis: higher mortality than patients with lupus and rheumatoid arthritis. Arthritis Care Res (Hoboken) 2014;66:323–7.
31. Nikpour M, Hissaria P, Byron J, Sahhar J, Micallef M, Paspaliaris W, et al. Prevalence, correlates and clinical usefulness of antibodies to RNA polymerase III in systemic sclerosis: a cross-sectional analysis of data from an Australian cohort. Arthritis Res Ther 2011;13:R211.